Skip to main content

Table 3 Included studies: baseline patient characteristics

From: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

  Lasmiditan vs placebo Rimegepant vs placebo Ubrogepant vs placebo
Characteristic SPARTAN Kuca et al. 2018
[15]
SAMURAI Goadsby
et al. 2019
[16]
CENTURION Ashina
et al. 2021
[17]
MONONOFU Sakai
et al. 2021
[18]
Färkkilä
et al. 2012 [19]
Study 301
Lipton
et al. 2018
[20]
Study 302
Lipton
et al. 2019
[21]
Study 303 Croop
et al. 2019
[22]
Marcus
et al. 2014
[23]
ACHIEVE I Dodick
et al. 2019
[24]
ACHIEVE II Lipton
et al. 2019
[25]
Voss
et al. 2016
[26]
Na (baseline) 1856 2583 1471 691 321 1162b 1072 1351 320 1436 1465 425
Female, n (%) 1552
(83.6)
2174
(84.2)
1236
(84)
574
(83.1)
277 (86.3) NA
(85.5)
951 (88.7) 1147
(84.9)
277
(86.6)
1266 (88.2) 1317 (89.9) 372 (87.5)
Meanc age, years (range)d 41.4–42.4 41.8–43.4 41.0–42.0 44.7–45.7 39.5–42.0 41.6d 40.2–40.9 40.0–40.3 37.9–38.5 40.1–40.9 41.2–41.7 40.5–41.9
Meanc duration of disease, years (range)d 18.9–19.7 17.6–19.2 NA 23.7–24.7 NA NA NA NA NA 17.9–19.1 18.1–19.2 NA
  1. aData are from patients receiving placebo or the active treatments included in the NMA; bNumber randomised; cMean for total study population; dRange is the range of mean values across each treatment group of interest
  2. NA not available, NMA network meta-analysis